Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

103.95 +0.05 (+0.04%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
BioNTech to Host Innovation Series R&D Day on November 11, 2025
From BioNTech SE
Via GlobeNewswire
BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025
From BioNTech SE
Via GlobeNewswire
BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.
From BioNTech SE
Via GlobeNewswire
BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025
From BioNTech SE
Via GlobeNewswire
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:CRSP),(NASDAQ:BNTX),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
From BioNTech SE
Via GlobeNewswire
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
From Pfizer Inc.
Via Business Wire
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
From Pfizer Inc.
Via Business Wire
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
From BioNTech SE
Via GlobeNewswire
BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union
From BioNTech SE
Via GlobeNewswire
BioNTech to Report Second Quarter 2025 Financial Results and Corporate Update on August 4, 2025
From BioNTech SE
Via GlobeNewswire
BioNTech Announces Ryan Richardson to Step Down from the Management Board
From BioNTech SE
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CureVac N.V. (Nasdaq - CVAC), Know Labs, Inc. (NYSE American - KNW), Volato Group, Inc. (NYSE American - SOAR), Heliogen, Inc. (OTC - HLGN)
From Brodsky & Smith LLC
Via GlobeNewswire
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer
From BioNTech SE
Via GlobeNewswire
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
From Bristol Myers Squibb
Via Business Wire
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
EQNX::TICKER_START (NNASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NASDAQ:BNTX),(NASDAQ:ARVN),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
From BioNTech SE
Via GlobeNewswire
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
From FN Media Group LLC
Via GlobeNewswire
BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting
From BioNTech SE
Via GlobeNewswire
BioNTech Announces First Quarter 2025 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer
From BioNTech SE
Via GlobeNewswire
BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025
From BioNTech SE
Via GlobeNewswire
BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025
From BioNTech SE
Via GlobeNewswire
BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
BioNTech to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on March 10, 2025
From BioNTech SE
Via GlobeNewswire
BioNTech Completes Acquisition of Biotheus
From BioNTech SE
Via GlobeNewswire
BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
From BioNTech SE
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.